Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Depreciation & Amortization (CF): 2024-2025

Historic Depreciation & Amortization (CF) for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $164,000.

  • Kura Oncology's Depreciation & Amortization (CF) fell 21.15% to $164,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $833,000, marking a year-over-year change of. This contributed to the annual value of $848,000 for FY2024, which is 0.12% down from last year.
  • Latest data reveals that Kura Oncology reported Depreciation & Amortization (CF) of $164,000 as of Q3 2025, which was down 26.79% from $224,000 recorded in Q2 2025.
  • Kura Oncology's Depreciation & Amortization (CF)'s 5-year high stood at $241,000 during Q1 2025, with a 5-year trough of $164,000 in Q3 2025.
  • Its 2-year average for Depreciation & Amortization (CF) is $211,000, with a median of $208,000 in 2024.
  • Data for Kura Oncology's Depreciation & Amortization (CF) shows a peak YoY increase of 10.89% (in 2025) and a maximum YoY decrease of 21.15% (in 2025) over the last 5 years.
  • Over the past 2 years, Kura Oncology's Depreciation & Amortization (CF) (Quarterly) stood at $204,000 in 2024, then declined by 21.15% to $164,000 in 2025.
  • Its last three reported values are $164,000 in Q3 2025, $224,000 for Q2 2025, and $241,000 during Q1 2025.